Lantheus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Lantheus and other ETFs, options, and stocks.

About LNTH

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. 

CEO
Mary Anne Heino
CEOMary Anne Heino
Employees
1,193
Employees1,193
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
1956
Founded1956
Employees
1,193
Employees1,193

LNTH Key Statistics

Market cap
6.51B
Market cap6.51B
Price-Earnings ratio
24.10
Price-Earnings ratio24.10
Dividend yield
—
Dividend yield—
Average volume
987.78K
Average volume987.78K
High today
$99.99
High today$99.99
Low today
$99.72
Low today$99.72
Open price
$99.92
Open price$99.92
Volume
828.29K
Volume828.29K
52 Week high
$111.86
52 Week high$111.86
52 Week low
$49.67
52 Week low$49.67

Stock Snapshot

Lantheus(LNTH) stock is priced at $99.74, giving the company a market capitalization of 6.51B. It carries a P/E multiple of 24.10.

On 2026-09-25, Lantheus(LNTH) stock moved within a range of $99.72 to $99.99. With shares now at $99.74, the stock is trading +0.0% above its intraday low and -0.3% below the session's peak.

Trading volume for Lantheus(LNTH) stock has reached 828.29K, versus its average volume of 987.78K.

The stock's 52-week range extends from a low of $49.67 to a high of $111.86.

The stock's 52-week range extends from a low of $49.67 to a high of $111.86.

LNTH News

Simply Wall St 2d
Lantheus Holdings Wins FDA Approval For BRAVNETSA, Is 7% Undervalued Enough? - simplywall.st

...

Lantheus Holdings Wins FDA Approval For BRAVNETSA, Is 7% Undervalued Enough? - simplywall.st
TipRanks 4d
Lantheus announces U.S. FDA granted final approval for Bravnesta

Lantheus (LNTH) announced that the U.S. Food and Drug Administration, FDA, has granted final approval for Bravnesta, a bioequivalent and therapeutically equival...

TipRanks 4d
Lantheus Merger Advances with Renewed Antitrust Review

Lantheus ( (LNTH) ) has shared an update. On August 3, 2026, Lantheus Holdings, Inc. agreed to be acquired through a merger with Curium US Holdings LLC, under...

Analyst ratings

80%

of 10 ratings
Buy
20%
Hold
80%
Sell
0%

People also own

Based on the portfolios of people who own LNTH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.